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ABSTRACT The MtrCDE efflux pump of Neisseria gonorrhoeae contributes to gono-
coccal resistance to a number of antibiotics used previously or currently in treat-
ment of gonorrhea, as well as to host-derived antimicrobials that participate in in-
nate defense. Overexpression of the MtrCDE efflux pump increases gonococcal
survival and fitness during experimental lower genital tract infection of female mice.
Transcription of mtrCDE can be repressed by the DNA-binding protein MtrR, which
also acts as a global regulator of genes involved in important metabolic, physiologic,
or regulatory processes. Here, we investigated whether a gene downstream of
mtrCDE, previously annotated gdhR in Neisseria meningitidis, is a target for regulation
by MtrR. In meningococci, GdhR serves as a regulator of genes involved in glucose
catabolism, amino acid transport, and biosynthesis, including gdhA, which encodes
an L-glutamate dehydrogenase and is located next to gdhR but is transcriptionally
divergent. We report here that in N. gonorrhoeae, expression of gdhR is subject to
autoregulation by GdhR and direct repression by MtrR. Importantly, loss of GdhR sig-
nificantly increased gonococcal fitness compared to a complemented mutant strain
during experimental murine infection. Interestingly, loss of GdhR did not influence
expression of gdhA, as reported for meningococci. This variance is most likely due to
differences in promoter localization and utilization between gonococci and menin-
gococci. We propose that transcriptional control of gonococcal genes through the
action of MtrR and GdhR contributes to fitness of N. gonorrhoeae during infection.
IMPORTANCE The pathogenic Neisseria species are strict human pathogens that
can cause a sexually transmitted infection (N. gonorrhoeae) or meningitis or fulmi-
nant septicemia (N. meningitidis). Although they share considerable genetic informa-
tion, little attention has been directed to comparing transcriptional regulatory sys-
tems that modulate expression of their conserved genes. We hypothesized that
transcriptional regulatory differences exist between these two pathogens, and we
used the gdh locus as a model to test this idea. For this purpose, we studied two
conserved genes (gdhR and gdhA) within the locus. Despite general conservation of
the gdh locus in gonococci and meningococci, differences exist in noncoding se-
quences that correspond to promoter elements or potential sites for interacting with
DNA-binding proteins, such as GdhR and MtrR. Our results indicate that implications
drawn from studying regulation of conserved genes in one pathogen are not neces-
sarily translatable to a genetically related pathogen.
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Neisseria gonorrhoeae is the etiologic agent of the sexually transmitted infection(STI) termed gonorrhea, which is the second most prevalent bacterial STI in the
United States and had a worldwide incidence of an estimated 78 million infections in
2012 (1). The capacity of gonococci to develop resistance to antibiotics is now of great
concern with the recent emergence of strains resistant to current and past frontline
antibiotics (2–5). With respect to the clinical efficacy of antibiotic treatment regimens,
evidence has been presented that overproduction of the gonococcal MtrCDE efflux
pump due to cis- or trans-acting mutations that elevate transcription of mtrCDE can
contribute to clinically relevant levels of antibiotic resistance (6–10).
The mtrR gene, which encodes the master repressor (MtrR) of the mtrCDE efflux
pump operon (8–10), is located immediately upstream of the mtrCDE operon (Fig. 1).
The mtrR and mtrCDE genes are oriented away from each other and have overlapping
promoters. Transcription of mtrCDE is repressed when MtrR is bound to the mtrCDE
promoter, which overlaps themtrR promoter (7, 8). Point mutations in the MtrR-binding
site (8, 10), a single base pair deletion within a 13-bp inverted repeat sequence in the
mtrR promoter (7), a point mutation that creates a new promoter (9), or missense
mutations that cause radical amino acid replacements within the helix-turn-helix
DNA-binding motif of MtrR can increase mtrCDE expression and antimicrobial resis-
tance (8, 10). Such elevated expression of mtrCDE also increased gonococcal fitness in
vivo when assessed by use of an experimental female murine lower genital tract
infection model (11). In addition to regulatingmtrCDE, MtrR serves as a global regulator
of gonococcal genes (12) and directly or indirectly activates or represses at least 65
genes outside themtrCDE locus. Included in these so-called “off-target” genes are those
that are involved in the stress response (rpoH), amino acid synthesis (glnA and glnE),
peptidoglycan biosynthesis (ponA), and regulation of gene expression (farR); the reg-
ulatory properties of MtrR have been summarized elsewhere (2, 13).
Our analysis of the whole-genome sequence of strain FA1090 (http://www.genome
.ou.edu) revealed an open reading frame (termed NGO 1360) positioned 943 bp
downstream of the mtrCDE operon that encodes a transcriptional regulator previously
annotated GdhR in Neisseria meningitidis (Fig. 1). GdhR belongs to the bacterial GntR
family of proteins, which serve as gene regulators and contain a highly conserved
N-terminal DNA-binding domain and a variable C-terminal domain involved in effector
binding and oligomerization (14). In N. meningitidis, which causes often deadly men-
ingitis or fulminant septicemia (15), GdhR regulates the expression of a number of
genes, some of which are involved in metabolism (16, 17). Meningococcal GdhR has
been reported to activate gdhA, which encodes an NADP-specific L-glutamate dehy-
drogenase (16). Given the prominent role of MtrR in modulating gonococcal resistance
to antimicrobials, its control of genes involved in metabolism, its influence on the
fitness of gonococci in an experimental infection model, and its proximity to gdhR, we
tested the capacity of MtrR to regulate expression of gdhR in N. gonorrhoeae, as well as
the ability of GdhR to regulate genes in the gdh locus (gdhR and gdhA). Our results
suggest that gonococcal and meningococcal GdhRs have distinct regulatory properties
that are driven by differences in promoter utilization of regulated genes and emphasize
FIG 1 The organization of the gonococcal mtr and gdh loci in N. gonorrhoeae strain FA19, highlighting
the position of genes relevant to this study. The length (shown in base pairs) and transcriptional
orientation (direction of arrows) of relevant genes are shown. Numbers above the horizontal line refer to
the coding regions of the gene, while the sizes of the intergenic regions (shaded boxes) are shown
below. The distance between the two loci is 954 bp.
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the importance of bacterial species-specific studies for examining regulatory properties
of a common DNA-binding protein.
RESULTS
The gdh locus in N. gonorrhoeae. Similar to N. meningitidis, the gdh locus in
N. gonorrhoeae FA19 is positioned 954 bp downstream from the mtr locus (Fig. 1) and
contains two open reading frames, gdhR, which encodes a GntR-like DNA-binding
protein, and gdhA, which encodes L-glutamate dehydrogenase. The gonococcal GdhR
and GdhA proteins are 97% and 98% identical, respectively (data not shown) to the
equivalent proteins described for meningococci (16). The end of gdhA is positioned
238 bp from the end of gdhR and is transcribed in the opposite direction; transcription
of gdhA has been reported to be activated by GdhR in meningococci (16).
Bioinformatic analysis (http://www.ncbi.nlm.nih.gov) revealed that the 200 bp up-
stream of gdhR in five gonococcal strains (FA19, FA1090, MS11, FA6140, and F89) were
identical, except for a C-to-T change in FA1090 29 bp upstream of the translation start
codon but after the transcription start site (TSS) (see below). In these same gonococcal
strains, 100% identity was noted for the 500-bp sequence upstream of gdhA (data not
shown). When the same regions from N. meningitidis strain MC58 in the corresponding
upstream regions of gdhR and gdhA were used in a BLAST search against whole-
genome sequences, two other meningococcal isolates (LNP21362 and H44/76) were
found to have identical sequences, while 10 others showed 99% identity (data not
shown). Thus, our use of gonococcal strain FA19 for comparison to meningococcal
strain MC58 is suitable for determining differences in regulation of the gdh locus in
these pathogens. Although the DNA sequences of the gdh loci in gonococci and
meningococci are very similar, important differences exist, especially in the location of
promoters and potential cis-acting regulatory sequences (see Fig. 3 for the CE insertion
in the meningococcal gdhR and see Fig. 6 for the gdhA promoters, respectively). We
hypothesized that the differences in these sequences between gonococci and menin-
gococci could impact GdhR-mediated regulation of gene expression in gonococci and
influence gonococcal biology. Accordingly, we sought to identify a phenotype that is
linked to GdhR production in gonococci and then to examine regulation of gdhR
expression and the capacity of GdhR to control model genes.
Loss of GdhR impacts in vivo fitness of gonococci independently of the mtr
locus. Given the close location of gdhR to themtr locus (Fig. 1), we determined whether
expression of GdhR influences transcription of mtrCDE and resistance of gonococci to
antimicrobials recognized by the MtrCDE efflux pump (2, 6–12). For this purpose, we
constructed a gdhR null mutant as well as a complemented strain. We found that the
wild-type parent (FA19), the gdhR::kan mutant, and the complemented strain displayed
identical levels of susceptibility to antimicrobials (erythromycin [Erm] MIC, 0.25 g/ml;
penicillin MIC, 0.015 g/ml; Triton X-100 MIC, 100 g/ml), and these MICs varied
according to the levels of the MtrCDE efflux pump (6, 7, 11, 18). Moreover, results from
quantitative reverse transcription-PCR (qRT-PCR) experiments indicated that expression
of mtrC (the first gene in the mtrCDE operon [Fig. 1]) was not impacted by loss of GdhR
(data not shown).
We also assessed the fitness of the gdhR mutant relative to wild-type and comple-
mented mutant bacteria during competitive infection of the lower genital tract of
female BALB/c mice. Mice were inoculated vaginally with mixed bacterial suspensions
containing similar numbers of the strains to be subjected to competition (total CFU per
mouse, 106), and the number of each strain of bacteria recovered from vaginal swab
suspensions on days 1, 3, and 5 postinoculation was expressed as a competitive index
(CI), as described in Materials and Methods. Ninety percent of the mice were colonized
throughout the 5-day study period, with 104 to 105 CFU/vaginal swab suspension
recovered from the majority of mice on day 1 postinoculation and104 CFU/ml on day
5 postinoculation (see Fig. S1 in the supplemental material). There was no difference in
the relative fitness of the wild-type parental strain bacteria and the complemented
gdhR::kan mutant strain (Fig. 2C). Interestingly, however, the gdhR::kan mutant strain
Regulation of gdhR in Gonococci ®
March/April 2017 Volume 8 Issue 2 e00449-17 mbio.asm.org 3
was significantly more fit than the complemented gdhR mutant strain on days 1, 3, and
5 postinoculation (geometric mean CIs, 18, 49, and 81, respectively) (Fig. 2B) compared
to the CIs for mice infected with the complemented mutant versus the wild-type strain
(Fig. 2C). Competitive infections between the gdhR::kan mutant strain and the parental
strain also showed elevated CIs (geometric mean CIs, 3.4, 30, and 21 on days 1, 3, and
5 postinoculation) (Fig. 2A), although the differences were not statistically significantly
different from those for the complemented mutant strain versus the wild-type strain.
Consistent with the gdhR mutant strain outcompeting the GdhR-expressing bacteria in
vivo, only mutant CFU were recovered from some mice inoculated with wild-type or
complemented mutant bacteria mixed with the gdhR::kan mutant bacteria on days 3
and 5 (Fig. 2A and B, open circles). These results indicated that GdhR production
negatively influences the in vivo fitness of gonococci; importantly, loss of GdhR did not
impact the growth rate of gonococci in GC broth (data not shown). This result
FIG 2 Absence of the GdhR protein confers a fitness advantage in N. gonorrhoeae. Competitive vaginal
infections in female BALB/c mice with FA19Strr and FA19Strr gdhR::kan (A), FA19Strr gdhR::kanC3 and
FA19Strr gdhR::kan (B), and FA19Strr and FA19Strr gdhR::kanC3 (C). Vaginal swab suspensions were quan-
titatively cultured on days 1, 3, and 5 post-bacterial inoculation, and the number of CFU of each strain was
determined using selective agar as described in Materials and Methods. Each symbol corresponds to the CI
from an individual mouse; open circles and open triangles correspond to mice from which only mutant CFU
or wild-type CFU were recovered, respectively. Bars represent the geometric mean CI values. Combined
data from two experiments are shown, with data points from each experiment indicated in black or grey.
Open circles indicate that only the mutant strain was recovered from the vaginal swabs at the indicated
time point. Open triangles indicate that only the wild-type strain was recovered from the vaginal swabs at
the indicated time point. The differences in the median CI between the FA19Strr versus FA19Strr gdhR::kan
C3 and the FA19Strr gdhR::kan versus FA19Strr gdhR::kan C3 competitions were statistically significant on
day 1 (P  0.02), day 3 (P  0.07), and day 5 (P  0.03) postinfection, based on the Kruskal-Wallis test with
Dunn’s multiple comparisons test (GraphPad Prism). Comparisons of the FA19Strr versus FA19Strr gdhR::kan
competition with FA19Strr versus FA19Strr gdhR::kan C3 showed that the results approached but did not
reach a statistically significant difference; P values for days 3 and 5 in this comparison were 0.055 and 0.056,
respectively.
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suggested that GdhR may be a negative regulator of in vivo fitness; therefore, we
sought to determine how gdhR is regulated in gonococci and if GdhR controls expres-
sion of model genes (gdhR and gdhA) previously studied in meningococci (16).
MtrR is a direct repressor of gdhR expression. MtrR exerts transcriptional repres-
sion on the mtrCDE operon by binding to a promoter located upstream of mtrC (8, 19).
Given the close proximity of gdhR to the mtr locus in both gonococci and meningo-
cocci, we asked if MtrR regulates gdhR expression in gonococci. Although gdhR was not
previously assigned to be an MtrR-regulated gene in an earlier transcriptional profiling
study that employed gonococcal RNA prepared from mid-logarithmic-phase cultures
(12), we reexamined MtrR control of gdhR for two reasons. First, the presence of a
putative MtrR-binding site upstream of the gdhR gene (Fig. 3A) suggested such control
is possible. This MtrR-binding site (boxed in Fig. 3A) was 60% homologous to the
MtrR-binding site on the mtrC promoter region (Fig. 3B). Second, the work of Mercante
et al. (20) showed that a different transcriptional factor (MpeR) expressed in gonococci
displays growth phase-dependent regulons.
Results from qRT-PCR experiments indicated that deletion of mtrR increases gdhR
transcription, supporting the hypothesis that MtrR controls gdhR expression in gono-
cocci by functioning as a repressor of this gene in the late-logarithmic phase of growth
(Fig. 3C). Using primer extension (PE) analysis (see Fig. S2), we identified three gdhR
TSSs, positioned 73, 72, and 70 nucleotides upstream of the start of translation of gdhR.
These TSSs allowed us to identify a promoter element (5=-TAGAAT-3= for the 10
hexamer and 5=-TTGACG-3= for the 35 hexamer) 81 bp upstream of the ATG trans-
lational start codon (Fig. 3A). Importantly, the putative MtrR-binding site overlapped
the 10 hexamer sequence of the predicted gdhR promoter. Based on this promoter
mapping and the identification of a predicted MtrR-binding site within the putative
gdhR promoter, we tested if MtrR bound in a specific manner upstream of the gdhR
coding sequence, and we used an electrophoretic mobility shift assay (EMSA) for this
purpose. We found that 2 g of MBP-MtrR was sufficient to completely shift a
32P-labeled probe, termed R3/R2, that consisted of 393 bp of sequence upstream of the
gdhR translational start (Fig. 4, lane 2). In order to better localize the MtrR-binding site(s)
within this region, we performed a competitive EMSA with nonradioactive fragments of
the R3/R2 probe used in the aforementioned EMSA. Binding competition assays
showed that a smaller probe encompassing the gdhR promoter and its downstream
region (probe R4/R2 [Fig. 3A]) competed with MtrR binding to the labeled R3/R2 probe
FIG 3 (A) Promoter sequence of the gdhR gene in strain FA19. The10 and35 promoter elements, the start of translation (ATG), and the TSSs are represented
in blue. Primers are represented by arrows and the putative MtrR-binding site is framed in red. The insertion site of the CE in meningococci is represented in
red (TA). The putative GdhR-binding site is underlined in green. (B) Alignment of the MtrR putative binding sites upstream of gdhR and mtrC. Dots between
the two sequences indicate identical bases. (C) Quantitative RT-PCR results for gdhR in the wild type (WT) and a strain with mtrR deleted at the late-logarithmic
phase of growth. Error bars represent standard deviations of the means of two independent experiments. Normalized expression ratios (NER) were calculated
using 16S rRNA expression levels. *, P  0.0004.
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(Fig. 4, lanes 3 and 4), while a fragment located upstream of the promoter (R3/R5
[Fig. 3A]) did not (Fig. 4, lanes 5 and 6). Accordingly, we propose that MtrR represses
gdhR expression by binding within the promoter sequence that contains the predicted
MtrR-binding site.
GdhR regulation of model genes in gonococci. We selected two GdhR genes for
study: gdhR and gdhA, which constitute the gdh locus (Fig. 1). We chose these 2 genes
to test if gdhR is subject to autoregulation by its gene product and because gdhA has
been reported to be a GdhR-activated gene in meningococci (16) and is positioned near
gdhR in both pathogens.
Pagliarulo et al. (16) suggested that the meningococcal gdhR transcript originates in
a Correia element (CE) (21) located upstream of the gdhR gene. An examination of 23
publicly available gonococcal genome sequences revealed that this CE is absent in the
gdhR promoter region (data not shown). However, a putative GntR-like binding site
(5=-TGTCATTA-3=) was identified between the10 and the35 sites of the gonococcal
gdhR promoter overlapping the predicted MtrR-binding site (Fig. 3A, underlined in
green). In order to investigate autoregulation of gdhR, qRT-PCR analysis of total RNA
prepared from mid- and late-log-phase cultures of strains FA19 and FA19 gdhR::kan was
performed. The expression of gdhR was increased by 4-fold at mid-log phase and by a
little more than 2-fold at late-log phase in the GdhR-negative mutant compared to the
parental strain (Fig. 5A). We hypothesize that insertion of a CE upstream of gdhR in
meningococci, but not in gonococci, results in the utilization of distinct gdhR promoters
FIG 4 Competitive EMSAs. The MtrR-binding site located on fragment R4/R2 has the highest affinity for
the MtrR protein. Lanes: 1, probe R3/R2* alone; 2, probe R3/R2* plus 2 g of MtrR; 3, probe R3/R2* plus
2 g of MtrR plus 50 unlabeled R3/R2; 4, probe R3/R2* plus 2 g of MtrR plus 100 unlabeled R3/R2;
5, probe R3/R2* plus 2 g of MtrR plus 50 unlabeled R3/R5; 6, probe R3/R2* plus 2 g of MtrR plus
100 unlabeled R3/R5; 7, probe R3/R2* plus 2 g of MtrR plus 50 unlabeled R4/R2; 8, probe R3/R2* plus
2 g of MtrR plus 100 unlabeled R4/R2; 9, probe R3/R2* plus 2 g of MtrR plus 50 rnpB; 10, probe
R3/R2* plus 2 g of MtrR plus 100 rnpB. An asterisk indicates a radioactive probe. The location of the
different gdhR probes are shown in Fig. 3A.
FIG 5 Quantitative RT-PCR results with gdhR (A) or gdhA (B) in wild-type (WT) and gdhR-negative strains
at the mid- and late-logarithmic phases of growth. Error bars represent standard deviations from the
means of three independent experiments. Normalized expression ratios (NER) were calculated using 16S
rRNA expression. *, P  0.011; **, P  0.008; NS, not significant.
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by these two related pathogens. Therefore, competing mechanisms of gdhR regulation
by MtrR and GdhR itself may not occur in meningococci. In this respect, it is important
to note that most meningococci encode an MtrR protein that contains loss-of-function
mutations in mtrR (22, 23), while nearly 80% of gonococci encode a wild-type MtrR
(reviewed in reference 2).
Previous work indicated that expression of gdhA in meningococci is directed by two
promoters, only one of which is regulated by GdhR (16). The GdhR-activated promoter
of gdhA in meningococci has a putative GdhR-binding site (5=-TGTCAACA-3=) upstream
of the35 hexamer, based on similarity to the known GntR-binding site (5=-TGTcaACA-
3=; the lowercase letters refer to nucleotides that differ from consensus GntR-binding
site) in other bacteria (14); this site is also located in the corresponding gonococcal
sequence (underlined in Fig. 6). In order to investigate whether GdhR binds to this site
in gonococci, as was shown previously in meningococci, we performed EMSA compe-
tition analysis using purified gonococcal His-tagged GdhR protein. The results showed
that gonococcal GdhR binds specifically to a DNA fragment encompassing the GntR-
binding site present upstream of gdhA in gonococci (Fig. 7).
FIG 6 Alignment of gdhA promoters from gonococcal strain FA19 (top) and meningococcal strain MC58
(bottom). The TSSs determined by primer extension experiments for strain FA19 identified in this study
and that of MC58 as reported by Pagliarulo et al. (16) are represented in blue, green, and red, with their
respective putative promoter elements. The consensus binding sequence for the GntR protein is
underlined. The gdhA translation start site is represented in purple.
FIG 7 The GdhR protein binds to the gdhA promoter in a specific manner. Lanes: 1, probe PgdhA* alone;
2, probe PgdhA* plus 1 g of GdhR; 3, probe PgdhA* plus 1 g of GdhR plus 50 unlabeled PgdhA; 4,
probe PgdhA* plus 1 g of GdhR plus 100 unlabeled PgdhA; 5, probe PgdhA* plus 1 g of GdhR plus
50 unlabeled rnpB; 6, probe PgdhA* plus 1 g of GdhR plus 100 unlabeled rnpB. Asterisk refers to
radioactive probe.
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In meningococci, the presence of another gdhA TSS was detected 207 bp upstream
of the ATG translational start codon (represented in blue in Fig. 6). However, a
GdhR-binding site was not identified within or near this distal promoter in meningo-
cocci. Interestingly, we did not detect a TSS 207 bp upstream of the ATG in gonococci.
This could be due to the presence of a mutation which changes the10 hexamer from
5=-TAATTA-3= in meningococcal strain MC58 to 5=-TAACTA-3= in gonococcal strain
FA19. To determine if gonococci have an additional promoter(s) for gdhA transcription,
we used PE analysis to identify transcription start sites. The results suggested the
presence of two promoters (Fig. 6). We identified a TSS located 8 bp downstream from
a 10 hexamer that constitutes the homolog of the above-mentioned meningococcal
promoter (shown in red). We also identified three TSSs located upstream of a noncon-
sensus 10 hexamer (5=-ATTTGT-3=) that is spaced 17 nucleotides from a weak 35
hexamer (5=-ATATGG-3=) (represented in green in Fig. 6). Importantly, this putative
promoter has the previously identified GdhR-binding site (underlined sequence in
Fig. 6) between its 10 and 35 hexamer sequences. This second gonococcal pro-
moter was not identified in meningococci. Based on the location of the two putative
gdhA promoters in gonococci, GdhR could impact expression of gdhA from both
promoters through interaction with the identified GdhR-binding site.
Taken together, our promoter mapping studies suggest that differences exist re-
garding gdhA transcription in gonococci and meningococci and that a GdhR-binding
site influences gdhA transcription in gonococci. In order to assess promoter utilization
in gonococci and any influence of GdhR on gdhA transcription, we performed qRT-PCR
analysis on RNA prepared from strain FA19 and its isogenic gdhR::kan mutant at mid-
and late-logarithmic phases of growth. Unlike its influence on gdhR expression, loss of
GdhR did not impact gdhA expression in either mid-log- or late-log-phase cultures
(Fig. 5B). One explanation for why we did not observe changes in gdhA expression is
that GdhR binds upstream of the most proximal promoter (represented in red in Fig. 6)
and inhibits the binding of the RNA polymerase to the second gdhR promoter (repre-
sented in green in Fig. 6), but it does not interfere with transcription from the proximal
promoter, just as in meningococci. Consequently, when GdhR is present, the most
proximal promoter (represented in red in Fig. 6) is the primary promoter used for
transcription of gdhA. When GdhR is absent, the most distal promoter (green in Fig. 6)
becomes the primary promoter for gdhR transcription.
DISCUSSION
Our interest in gdhR was spurred by its close location to the mtr locus, which
encodes the tripartite RND-type efflux pump MtrC-MtrD-MtrE and a transcriptional
repressor (Fig. 1). We hypothesized that GdhR and MtrR might have cross-regulatory
activities on the mtr and gdh loci, respectively. While we did not find evidence that
GdhR regulates mtrCDE or antimicrobial resistance, we did find that its loss significantly
increased fitness of gonococci during an experimental infection of the lower genital
tract of female mice. This experimental model of infection has been used by us to show
the importance of the MtrCDE pump for gonococcal survival in vivo and that gradients
of fitness can be observed (11, 24), depending on the presence of distinct cis- or
trans-acting mutations that influence mtrCDE expression (2).
Although the observed increase in fitness in the gdhR-negative mutant of strain FA19
was not as dramatic as previous findings (11) with an mtrR-negative mutant (5- to 10-fold
versus ca. 100-fold), the impact on fitness was reproducible and significant. Therefore, we
sought to define regulatory systems that influence gdhR expression in gonococci, and we
compared our results with those obtained by others working on regulation of meningo-
coccal genes controlled by GdhR. We discovered two trans-acting regulatory systems that
were not previously observed in meningococci: (i) MtrR, which can directly repress expres-
sion of gdhR (Fig. 3), and (ii) GdhR, which can repress itself (Fig. 4). In the first instance, MtrR
regulation of gdhR emphasizes the global regulatory properties of this DNA-binding protein
in gonococci. It is noteworthy that this mechanism does not extend tomost meningococcal
isolates, since they harbor loss-of-function mutations in mtrR (22, 23). In the second
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instance, GdhR autoregulation of gdhRmay be unique to gonococci, because the presence
of a CE in this region in meningococci, but not gonococci, likely influences promoter
utilization and GdhR binding.
GdhR has been previously studied in meningococci for its capacity to regulate genes
involved in metabolism, but heretofore it has not been investigated for its regulatory
properties in gonococci. Although GdhR has been reported to activate expression of
gdhA and gltT, which encodes an L-glutamate transporter that appeared to be essential
for full virulence in a rodent model of invasive meningococcal disease (25), its capacity
to autoregulate its own gene or be controlled by trans-acting factors has not been
elucidated in either pathogen. The work presented here illustrates that although two
genetically related pathogens can encode the same transcription factor (e.g., GdhR) and
have conserved target genes (e.g., gdhA), gene regulatory principles that have evolved
for one pathogen may not necessarily apply to the related pathogen. Thus, although
the GdhRs in meningococci and gonococci are identical, regulation of one target, gdhA,
is distinct. While gdhA is a GdhR-activated gene in meningococci, based on quantitative
analysis of levels of mRNA transcripts, our work failed to reveal differences in gdhA
transcript levels in isogenic GdhR-positive and -negative gonococci. This does not mean
that GdhR cannot activate gdhA in gonococci. We draw this conclusion because PE
analysis suggested the presence of two promoters in gonococci that could direct
transcription and be differentially impacted (activated or repressed) by GdhR, thereby
giving the impression of lack of gdhA regulation. We propose that differences in the
DNA sequence in the gdh locus in gonococci versus meningococci result in distinct
promoter utilization and regulation.
Additional studies are needed to define the GdhR regulon in gonococci in order to
understand the role of this DNA-binding protein in controlling genes important for me-
tabolism and in vivo fitness of N. gonorrhoeae. In this respect, the increased fitness of the
gdhR mutant observed on days 3 and 5 (Fig. 2) corresponds to the time inflammation is
detected in the mouse model (26). With the protocol we use, proinflammatory cytokines
and chemokines begin to increase on day 3 and peak on day 5, along with a peak
polymorphonuclear leukocyte influx on day 5; expression of antimicrobial peptides also
peaks on day 5 (A. E. Jerse et al., unpublished data). Thus, it is possible that gdhR may
downregulate genes important in the invasion of innate defenses. Depression or induction
of genes that are important in growth and metabolism could also contribute to the
increased fitness observed with the gdhR mutant. With these possibilities in mind, which
form the basis for future studies, our results emphasize that pathogen-specific regulatory
actions of a common DNA-binding protein likely exist even between closely related
bacteria (e.g., gonococci versus meningococci) and that differences in gene control, which
could be influenced by cis-regulatory elements, may have consequences for the overall
biology of members in same genus.
MATERIALS AND METHODS
Gonococcal strains, growth conditions, and determination of susceptibility to antimicrobial
agents. Strains used in this study are presented in Table 1. Gonococcal strains were grown overnight at
37°C under 5% (vol/vol) CO2 on GC agar containing defined supplements I and II (27). Determination of
susceptibility of test strains to antibiotics was performed by the agar dilution method, and results were
reported as the MIC (18). Antibiotics were purchased from Sigma Chemical Co. (St. Louis, MO). Esche-
richia coli strains were grown overnight at 37°C on LB agar.
TABLE 1 Strains of Neisseria gonorrhoeae employed in this study
Strain Relevant genotype Source(s)
FA19 Wild type 18
JF1 FA19 with mtrR deleted 27, 34
FA19Strr FA19 with point mutation in rpsL 35
FA19Strr gdhR::kan FA19 with rpsL aphA1 inserted in gdhR This study
FA19Strr gdhR::kanC3 FA19 with rpsL aphA1 inserted in gdhR with wild-type
copy of gdhR at lctP-aspC genomic locus
This study
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Construction of the gdhR-negative mutant and its complemented strain. The plasmid construct
used to insertionally inactivate the gdhR gene was created in pUC18us, which is pUC18 containing the
10-bp uptake sequence preceding the HindIII site in the polylinker. Overlap extension PCR was used to
amplify the gdhR gene containing an internal XbaI site by using the upstream primer 5=GepR-new-Bam
(5=-AGAGGATCCTAGAAACTGGTAAGGCCTCAGA-3=) and midstream reverse primer 3=GepR-mid-XbaI (5=-
CTTCCTCAAACTTTTCTAGACAAAACCGAATCCGC-3=) to amplify the first half of the gene and the mid-
stream forward primer 5=GepR-mid-XbaI (5=-GCGGATTCGGTTTTGTCTAGAAAAGTTTGAGGAAG-3=) and the
downstream reverse primer 3=-gepR-EcoRI (5=-AGAGAATTCATACCTCCCAATCCTGCAC-3=) to amplify the
second half of the gene. The two midstream primers are complementary to one another, and so in
the second round of PCR, aliquots of each amplification product were used as the template with the
forward upstream and reverse downstream primers to generate the gdhR gene containing an XbaI site
in the middle of the gene. This modified gdhR construct was digested with EcoRI and BamHI and cloned
into similarly digested pUC18us in which the existing XbaI site was destroyed by cutting with XbaI, filling
in the 5=-overhangs with Klenow fragment, and religation. To create the gdhR inactivation construct, a
blunt-ended kanamycin (Kan) resistance cassette derived from pLG338 (28) was ligated into the
pUC18us-gdhR plasmid at the filled-in XbaI site in the middle of the gdhR gene. This construct was
linearized by digestion with EcoRI and used to transform FA19Strr (FA19 containing the rpsL allele from
FA1090 that confers resistance to streptomycin [Str]), with transformants selected on GC agar plates
containing 50 g/ml Kan and verified by colony PCR and sequencing.
The pGCC3 vector (29) was used to complement FA19Strr gdhR::kan because it allows the integration
of a wild-type copy of gdhR under its own promoter at the transcriptionally silent intergenic region
between lctP and aspC. pgntR3pac1 (5=-GATCTTAATTAAGCCGATTGCCGTGTAGTTTT-3=) and pme1gepR4
(5=-GATCGTTTAAACCCAGACCGTCTGAAC-3=) were used to amplify the gdhR gene. The resulting PCR
product was cloned into the pGCC3 vector. The pGCC3gdhR construct was verified by sequencing and
then transformed into FA19Strr gdhR::kan. FA19Strr gdhR::kanC3 transformants were selected on GC agar
plates supplemented with 1 g/ml of Erm and verified by colony PCR.
Competitive murine infection. Mixed bacterial inocula containing similar numbers of the two
strains being tested were prepared by harvesting test strains from GC agar plates grown for 18 to 21 h
and suspending the bacteria in 4 to 5 ml of 1 phosphate-buffered saline (PBS). The suspensions were
passed through a 1.2-m filter to remove bacterial aggregates and, using previously determined
standard values for each strain relating readings of the optical density at 600 nm (OD600) to CFU counts,
the bacterial suspensions were diluted to ~5 107 CFU/ml before being mixed in a 1:1 ratio (actual ratios
were determined by plating as described below). Female NCI BALB/c mice (6 to 8 weeks old; Charles
River, Inc.) in the diestrus stage or anestrus were injected subcutaneously with 0.5 mg of Premarin (Pfizer)
on days2, 0, and2. On day 0, the mice were inoculated vaginally with 20 l of the mixed suspension
(~1  106 to 2  106 CFU/mouse). Mice were also treated with Str, vancomycin, and trimethoprim as
described elsewhere (30) to suppress the overgrowth of commensal flora that occurs under the influence
of estrogen. The vaginas were gently swabbed with a PBS-moistened sterile swab on days 1, 3, and
5 postinfection, and the swab material was suspended in 1 ml of PBS. Serial dilutions were performed
in GC broth with 0.05% saponin, and dilutions were plated on GC agar with 100 g/ml of Str for
determination of total CFU, GC agar with 100 g/ml of Str and 50 g/ml Kan for determination of
FA19Strr gdhR::kan CFU, or 1 g/ml Erm for FA19Strr gdhR::kanC3 CFU. Plates were incubated overnight
at 37°C under 7% (vol/vol) CO2, and colonies were counted after 24 to 48 h. The number of CFU
recovered on GC-Str plus Kan or GC-Str plus Em agar plates was subtracted from the number of CFU
recovered on GC-Str agar to determine the number of wild-type/parent CFU recovered. The CI was
calculated according to the following equation: [(CFUMutant/CFUWt)Output]/[(CFUMutant/CFUWt)Input]. A value
of 20 CFU (limit of detection) was used to calculate the CI for cultures from which CFU from one of the
two strains were not recovered. Competitive infections were repeated, and the data were combined to
test reproducibility and increase the statistical power. The Kruskall-Wallis test with Dunn’s multiple-
comparisons test (GraphPad Prism) was used to compare the differences in the CIs for mice inoculated
with each mixture.
Animal experiments were conducted in the laboratory animal facility at USUHS, which is fully
accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, under a
protocol approved by the USUHS Institutional Animal Care and Use Committee.
Quantitative RT-PCR. For qRT-PCR analysis of transcript levels, RNA was extracted from strains FA19,
JF1 (FA19 ΔmtrR) (12), and FA19 gdhR::kan grown in GC broth with supplements to late-logarithmic
phase by the TRIzol method as directed by the manufacturer (Thermo Fisher Scientific, Waltham, MA).
Genomic DNA (gDNA) was removed by RNase-free DNase treatment and use of gDNA Wipeout (Qiagen,
Germantown, MD). The resulting RNA was then reverse transcribed to cDNA using the QuantiTect reverse
transcriptase kit (Qiagen). Quantitative real-time RT-PCR was performed using the generated cDNA, and
results were normalized to 16S rRNA expression for each strain. Primers 16Smai_qRTF (5=-CCATCGGTA
TTCCTCCACATCTCT-3=) and 16Smai_qRTR (5=-CGTAGGGTGCGAGCGTTAATC-3=) were used for the 16S
rRNA, while primers gdhR-qRT-R2 (5=-AACCGAATCCGCTTCAAATCGG-3=) and gepR_qRTF1 (5=-ATCAG
GTATTGTCGGTATTGGAAG-3=) were used for the gdhR gene. Primers gdhA_qRTF (5=-TTCCATCAGGCGGT
TGAAGAA-3=) and gdhA_qRTR (5=-TTTGTCGTCCTGCCAGGTTA-3=) were used for the gdhA gene. Both
gdhR-qRT-R2 and gepR_qRTF1 anneal upstream of the kanamycin cassette insertion, allowing their use
for qRT-PCR experiments that employ RNA extracted from the gdhR::kan mutant. Primers mtrC_qRT_F
(5=-CGGATTTGGCGCGTTACAAA-3=) and mtrC_qRT-R (5=-TAATGCGCGAACGGTTCAGA-3=) were used for
the mtrC gene. All qRT-PCRs were performed in experimental duplicates and biological duplicates or
triplicates.
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Mapping transcriptional start sites by primer extension analysis. Total RNA from strain FA19 was
prepared at the late-logarithmic phase of growth in GC broth as described above, using the method of
Baker and Yanofsky (31). Primer extension experiments were performed as described previously (7) with
6 g of total RNA with primers PEgntR (5=-CCAGTTTCATCACTCCTCCT-3=) or PEgdhA (5=-TTTGAGGTTGG
CAAACAGGG-3=). The AMV reverse transcriptase primer extension system from Promega (Madison, WI)
was used as described by the manufacturer. The TSSs were determined via electrophoresis of the
extension products on a 6% (wt/vol) DNA sequencing acrylamide gel adjacent to reference sequencing
reaction mixtures.
Purification of the GdhR protein. Construction of pET15bgdhR was done by amplifying the gdhR
open reading frame using the primers gdhR_F (5=-GATCGCCATATGAAACTGGTAAGGCCTCAG-3=) and
gdhR_R (5=-GCGGATCCTCATACCTCCCAATCCTG-3=). The resulting PCR product along with the pET15b
vector were digested with NdeI and BamHI, ligated overnight, and transformed into E. coli DH5. The
pET15bgdhR construct was confirmed by sequencing with vector-specific primers T7F (5=-TTAATACGAC
TCACTATAGG-3=) and T7R (5=-GCTAGTTATTGCTCAGCGG-3=).
For protein expression, pET15bgdhR was transformed into E. coli BL21(DE3) cells. Cultures (5 ml) of
BL21(DE3)-pET15bgdhR cells were grown overnight at 30°C and added to 500 ml of LB broth the next
morning. The culture was grown at 30°C until mid-log phase and then induced with 0.3 mM isopropyl-
-D-thiogalactopyranoside and grown overnight at 30°C. Cells were harvested and resuspended in 20 ml
of 10 mM Tris (pH 7.5), 200 mM NaCl, and then EDTA-free protease inhibitor was added to the bacterial
suspension. The cells were lysed by use of a French press cell as described elsewhere (32), membranes
and unbroken cells were removed by centrifugation at 100,000  g, and the supernatant was collected
and filtered. GdhR-His was purified over a 2-ml nickel-nitrilotriacetic acid (Ni2-NTA) column. After
flowing the supernatant over the Ni2-NTA column, the resin was washed successively with buffer
containing 20 mM and 50 mM imidazole to remove contaminants and weakly bound proteins, and
GdhR-His was eluted successively with buffer containing 100 and 200 mM imidazole. The fractions
containing GdhR-His were concentrated and the imidazole-containing buffer was removed by dialysis
into storage buffer (10 mM Tris-HCl [pH 7.5], 200 mM NaCl, and 1 mM EDTA). Dithiothreitol and glycerol
were added to final concentrations of 1 mM and 10%, respectively. To verify the stability and purity of
the GdhR and MtrR fusion proteins, we subjected 1 g of purified proteins to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using a 12% (wt/vol) polyacrylamide gel (33), and
then stained the resolved proteins with Coomassie brilliant blue (CBB). Each protein preparation
contained a single CBB-staining band; the respective proteins migrated in the SDS-PAGE gel with a
molecular mass consistent with their fusion protein status (32.0 kDa for GdhR-His and 65 kDa for
MtrR-MBP [data not shown]).
EMSA. DNA probes encompassing the gdhR or the gdhA promoter regions that were used in the
EMSAs were amplified by PCR from FA19 genomic DNA using the upstream primer R3 (5=-CGCCGATTG
CCGTGTAGTTTT-3=) or R4 (5=-TGCCGTTGACGGCGGGAACGG-3=) and the downstream primer R2 (5=-GTT
TCATCACTCCTCCTTTAT-3=) or R5 (5=-CCGTTCCCGCCGTCAACGGCA-3=) for gdhR (relative to the direction
of transcription) and P1958F (5=-GTTGTTGGCAATTTCAGCCCTT-3=) and P1358R (5=-CGTCATTCGGATACTC
CTTTT-3=) for gdhA. When making radioactive probes, the indicated PCR products were labeled with
[32P]dATP using T4 polynucleotide kinase (New England Biolabs). The labeled DNA fragments were
incubated with 2 g of MtrR-MBP, purified as described previously (8, 22), or with 1 g of GdhR-His, in
30 l of reaction buffer at room temperature. For the competition assays, the same nonlabeled probe or
a nonlabeled PCR product along with rnpBF1 (5=-CGGGACGGGCAGACAGTCGC-3=) and rnpBR1 (5=-GGA
CAGGCGGTAAGCCGGGTTC-3=) primers were added to the reaction mixture. Samples were subjected to
electrophoresis in a 6% native polyacrylamide gel at 4°C, followed by autoradiography.
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